2009 Annual Monday

Orlando, FL - ASCO 2009 Annual Meeting: Andrew D Seidman, MD discusses Abstract 1000 - Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). during the Oral Presentation at the American Society for Clinical Oncology Annual Meeting here today, Monday June 1, 2009. Over 25,000 physicians, researchers and healthcare professionals from over 80 countries are attending the meeting which is being held at the Orange County Convention center and features the latest cancer research in the areas of basic and clinical science. Date: Monday June 1, 2009 Photo by � ASCO/Scott Morgan 2009 Technical Questions: todd@toddbuchanan.com; Phone: 612-226-5154.